Home
Superbugs & Superdrugs - A Focus on Antibacterials
20 March - 21 March 2017
Superbugs & Superdrugs - A Focus on Antibacterials

SUPERBUGS & SUPERDRUGS 2017

2 DAY CONFERENCE: 20TH & 21ST MARCH
2 INTERACTIVE WORKSHOPS: 22ND MARCH (For details visit the ASSOCIATED EVENTS tab)


SAE Media Group is proud to present the 2017 19th annual Superbugs & Superdrugs conference, taking place on 20th and 21st March in Central London.
Expanding horizons on the growing threat of anti-microbial resistance for almost two decades, the flagship show in the global Superbugs portfolio of events will once again play host to an international audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities.

Each year, around 2 million people are taken ill in the US from antibiotic-resistant bacteria and kills at least 23,000, according to estimates by the Centers for Disease Control and Prevention. The threat is so high that in September 2014 President Barack Obama issued an executive order Combating Antibiotic-Resistant Bacteria. *

The threat is the same in Europe, big pharmaceutical companies are re-entering the space into development of new antibiotics after decades. In January 2016, more than 80 pharmaceutical, biotechnology and diagnostics companies including Roche, Pfizer, Novartis AG and GlaxoSAE Media GroupthKline pledged at the World Economic Forum to fight the threat of antimicrobial resistance.*

The industry’s premier event on antibiotic resistance will provide a perfect platform for its growing "superbugs" community to network, exchange novel solutions and consolidate current strategies. A must attend for both new and seasoned stakeholders involved in AMR and infectious disease.

https://www.fredhutch.org/en/news/center-news/2015/01/combating-superbugs-superdrugs-antibiotics.html
http://www.iol.co.za/business/international/big-pharma-drawn-back-to-antibiotics-2040209

PREVIOUS ATTENDEE TESTIMONIALS FROM SUPERBUGS & SUPERDRUGS 2016

  • “Great meeting to network and have time to discuss face to face. Key questions and issues. Very collaborative open meeting.” – Roche
  • “It was one of the most useful scientific conferences that I have attended” – BARDA
  • “Good mix of problems such as funding and novel opportunities and success stories” – TNO
  • “I enjoyed attending the meeting this year and wanted to thank you for your efforts in organizing it” – UNT Health Science Centre
  • “I like the mix of early stage technologies and also later stage products being presented” – Sempra Pharmaceuticals

FEATURED SPEAKERS

Aileen  Rubio

Aileen Rubio

Head of Biology, Spero Therapeutics
Christopher Houchens

Christopher Houchens

Branch Chief, Antibacterials Program, BARDA
Dr Andrew Bristol

Dr Andrew Bristol

Vice President of Development, Synthetic Biologics, Inc.
Eszter Nagy

Eszter Nagy

President and CSO, Arsanis Biosciences GmbH
Jean de Gunzburg

Jean de Gunzburg

CSO, Da Volterra
Richard Bax

Richard Bax

Senior Partner, TranScrip Partners

Aaron Dane

Director, Danestat consulting
Aaron Dane

Aileen Rubio

Head of Biology, Spero Therapeutics
Aileen  Rubio

Anthony Maxwell

Professor, John Innes Centre
Anthony Maxwell

Christopher Houchens

Branch Chief, Antibacterials Program, BARDA
Christopher Houchens

David Williams

Chief Executive Officer, Discuva
David Williams

Deborah O'Neil

Chief Executive Officer, Novabiotics Ltd
Deborah O'Neil

Dr Andrew Bristol

Vice President of Development, Synthetic Biologics, Inc.
Dr Andrew Bristol

Andrew Bristol, Ph.D., is currently the Vice-President of Development at Synthetic Biologics, Inc. in Rockville, MD. He has more than 20 years experience in biological drug development in research, development and manufacturing. Dr. Bristol is currently interested in elucidating mechanisms of microbial drug resistance and developing active agents to protect the gut microbiome from antibiotic-associated dysbiosis. He has developed multiple biologicals products in various phases of clinical testing - including peptides, viral vectors and recombinant monoclonal antibodies and proteins.

Eszter Nagy

President and CSO, Arsanis Biosciences GmbH
Eszter Nagy

James Anderson

Head of Government Affairs, GSK
James Anderson

Jean de Gunzburg

CSO, Da Volterra
Jean de Gunzburg

Kai Hilpert

Prof Associate Reader in Infection and Immunology , St George's, University of London
Kai Hilpert

Lloyd Czaplewski

Director, Chemical Biology Ventures
Lloyd Czaplewski

Martin Everett

Chief Scientific Officer , Antabio
Martin Everett

Michael McArthur

Chief Scientific Officer, Procarta Biosystems Ltd.
Michael McArthur

Nicole Mahoney

Global Regulatory Policy, MSD
Nicole  Mahoney

Dr. Nicole Mahoney is Director, Global Regulatory Policy at MSD. Her work is focused on leading MSD’s efforts in guiding U.S. and international regulatory policy on infectious disease therapies. In this capacity, she supports cross-functional teams responsible for the company’s portfolio of investigational and approved antibacterial medicines, providing strategic input on key issues throughout the life-cycle of these products.
Nicole also represents the company on the Innovative Medicine Initative’s Driving re-investment in R&D and responsible use of antibiotics (DRIVE-AB) project, a joint undertaking by the EU and European Pharmaceutical Industry Association focused on spurring antibiotic innovation and research.
Prior to joining MSD, Nicole served as the senior officer for the Pew Charitable Trusts' antibiotics and innovation project and as a U.S. Food and Drug Administration Commissioner’s Fellow in the FDA’s Office of Antimicrobial Products, analyzing trends in the regulatory process for all new antibiotics reviewed by the agency over three decades. She earned her PhD in biochemistry from the Albert Einstein College of Medicine and completed postdoctoral training at the University of California, San Francisco.
 

Oreola Donini

Chief Scientific Officer, Soligenix, Inc.
Oreola Donini

Oreola Donini has more than 15 years experience in drug discovery and preclinical development with start-up biotechnology companies and has been instrumental in leading early stage development of several novel therapies into the clinic. Dr. Donini has worked previously with ESSA Pharma Inc., Inimex Pharmaceuticals Inc. and Kinetek Pharmaceuticals Inc., developing novel therapies for infectious disease, cancer and cancer supportive care. Dr. Donini is a co-inventor and leader of the SGX94 Innate Defense Regulator technology. She was responsible for overseeing the manufacturing and preclinical testing of SGX94, which demonstrated efficacy in combating bacterial infections and mitigating the effects of tissue damage due to trauma, infection, radiation and/or chemotherapy treatment. These preclinical studies culminated in a successful Phase 1 and Phase 2 clinical studies demonstrating efficacy in reducing the duration of severe oral mucositis in head and neck cancer patients (a function of a dysregulated inflammatory innate immune response) and an ability to reduce the rate of infections in these same patients. While with ESSA Pharma as the Vice President of Research and Development, Dr. Donini led the preclinical testing of a novel N-terminal domain inhibitor of the androgen receptor for the treatment of prostate cancer. She has previously worked in immunology and oncology. Dr. Donini received her PhD from Queen’s University in Kinston, Ontario, Canada and completed her post-doctoral work at the University of California, San Francisco. Her research has spanned drug discovery, preclinical development, manufacturing and clinical development in infectious disease, cancer and cancer supportive care.
 

Richard Bax

Senior Partner, TranScrip Partners
Richard Bax

Richard Rutter

Chief Scientific Officer, Auspherix Ltd
Richard Rutter

Ron de Winter

Project leader, UMC Utrecht
Ron de Winter

Sumathi Nambiar

Director, Division of Anti-Infective, FDA
Sumathi Nambiar

William Weiss

Director of Pre-Clinical Services, University of North Texas Health Science Center
William Weiss

Bill Weiss is currently the Director of Preclinical Services at the University of North Texas Health Science Center in Fort Worth. He uses his 33 years of experience and expertise in infectious disease research to direct the evaluations of antibacterial agents, including established models of both acute and chronic bacterial infections in several different animal species as well as pharmacokinetic studies and HPLC or LCMS analysis in collaboration with large pharmaceutical companies, the biotech industry as well as academia. Prior to this, he was Director of Drug Evaluation at Cumbre Pharmaceuticals Inc. His responsibilities included animal efficacy models, pharmacology and all pre-clinical microbiology research and development efforts focused on the discovery and development of new antimicrobial agents. Previously, he was a Group Leader in Infectious Disease Discovery Research at Wyeth Research, Lederle Laboratories and Schering-Plough and has held various positions of responsibility in antibacterial, antiviral and antifungal discovery research. He has worked on numerous antibacterial programs including the development of the marketed products, Suprax, Zosyn and Tygacil. His expertise encompasses the development and evaluation of animal models of infectious disease as well as pharmacokinetic and pharmacodynamic analysis. He has authored / co-authored over 90 research presentations and journal articles.

Xavier Duportet

CEO, Eligo Bioscience
Xavier Duportet

sponsors

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

William Weiss

William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

Mark  Pulse

Mark Pulse, Assistant Director , University of North Texas Health Science Center

clock

9:10

Pre-Clinical Drug Development

• Overview of preclinical testing
• Discovery to lead selection
• The development model: then and now
• Antibacterial research efforts
 

William Weiss

William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

Mark  Pulse

Mark Pulse, Assistant Director , University of North Texas Health Science Center

clock

9:50

Experimental Design and Methodology

• Experimental design profoundly influences
the outcome of a research study
• Clearly define the question or problem
being studied
• Realistic objectives (achievable)
• Choose the best research model

William Weiss

William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

Mark  Pulse

Mark Pulse, Assistant Director , University of North Texas Health Science Center

clock

10:30

Morning Coffee

clock

11:00

Animal Models – Examples

• Acute infection models – Bacteremia, Sepsis
• Chronic infection models – Pneumonia, skin,
abscesses
• GI related – C. difficile, H. pylori

William Weiss

William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

Mark  Pulse

Mark Pulse, Assistant Director , University of North Texas Health Science Center

clock

12:20

Animals in Research

• Institutional Animal Care and Use Committee
(IACUC)
• Justify why animals are necessary, minimize pain
and distress, husbandry and care
• Use of appropriate euthanasia methods
• The 3 R’s

William Weiss

William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

Mark  Pulse

Mark Pulse, Assistant Director , University of North Texas Health Science Center

clock

12:30

Close of Workshop

William Weiss

William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

Mark  Pulse

Mark Pulse, Assistant Director , University of North Texas Health Science Center

clock

13:30

Registration & Coffee

clock

13:45

Opening remarks and introductions

Keith Williams

Keith Williams, Consultant , Boyds

clock

14:00

Target product profi les - what new products are needed and how are TPPs created. Advisory boards, market research, planning for 10-15 years ahead

Keith Williams

Keith Williams, Consultant , Boyds

clock

15:00

Afternoon Tea

clock

15:30

Selecting drug targets and evaluating hits & optimising potential lead compounds

Keith Williams

Keith Williams, Consultant , Boyds

clock

16:00

Getting into man and setting the therapeutic dose

Keith Williams

Keith Williams, Consultant , Boyds

clock

17:00

Global clinical developments - challenges

Keith Williams

Keith Williams, Consultant , Boyds

clock

17:30

Regulatory and international hurdles: Reasons drugs fail in development

Keith Williams

Keith Williams, Consultant , Boyds

clock

17:50

Close of workshop

Keith Williams

Keith Williams, Consultant , Boyds

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Richard Bax

Richard Bax, Senior Partner, TranScrip Partners

clock

9:10

Regulatory perspective on antibacterial drug development

Sumathi Nambiar

Sumathi Nambiar, Director, Division of Anti-Infective, FDA


-Discuss streamlined development programs
-Activities to facilitate antibacterial drug development
-Discuss some remaining challenges in antibacterial drug development    
 

clock

9:50

Repopulating the Antibacterial Pipeline

Christopher Houchens

Christopher Houchens, Branch Chief, Antibacterials Program, BARDA

• What is BARDA?
• Why BARDA is interested in antimicrobial resistance (AMR)
• How BARDA is addressing the issue of AMR
• Forming innovative public-private partnerships to
accelerate clinical product development
• Stimulating innovation in early stage antimicrobial
research and development

clock

10:30

Morning Coffee

clock

10:50

SYN-004 (ribaxamase): A Novel Orally Delivered Therapy Designed to Protect the Gut Microbiome from the Detrimental Effects of Intravenous ß-lactam Antibiotics

Dr Andrew Bristol, Vice President of Development, Synthetic Biologics, Inc.

  • Antibiotics cause disruption of the gut microbiome, which can lead to C.diff infection
  • SYN-004 (ribaxamase) is a b-lactamase enzyme developed to inactivate b-lactam antibiotics excreted into the intestine before reaching the colon
  • Presentation of preclinical study results in pigs demonstrating prevention of dysbiosis by SYN-004, and prevention of emergent antibiotic-resistance genes
  • Presentation of clinical study results, Phase 1 and Phase 2 studies
  • Future plans, including b-lactamase formulation compatible with oral b-lactams, development of carbapenemase (SYN-006)
  • clock

    11:30

    Sequence-specific antimicrobials for targeted eradication of carriage

    Xavier Duportet

    Xavier Duportet, CEO, Eligo Bioscience

    clock

    12:10

    Networking Lunch

    clock

    13:10

    Innate defense regulators: Agnostic therapy for antibiotic resistant disease

    Oreola Donini, Chief Scientific Officer, Soligenix, Inc.

  • Innate immunity is a complementary approach for treatment of bacterial infectious diseases
  • Preclinical studies demonstrated an ability to combat infection, irrespective of the infectious bacterial pathogen, whether Gram-positive or Gram-negative, intracellular or extracellular, or antibiotic sensitive or resistant while modulation of inflammation and enhanced tissue healing were also observed
  • Clinically, the lead clinical IDR, dusquetide, has been demonstrated to be safe and efficacious in Phase 1 and 2 studies.
  • In a Phase 2 study, dusquetide reduced the duration of severe oral mucositis in head and neck cancer patients receiving chemoradiation therapy, while also decreasing the incidence of bacterial infections.
  • clock

    13:50

    EU COMBACTE Consortium: Combatting bacterial resistance in Europe in a public-private partnership

    Ron de Winter

    Ron de Winter, Project leader, UMC Utrecht

  • Part of EU action plan New Drugs for Bad Bugs (ND4BB) against the rising threats from Antimicrobial Resistance
  • improving the efficiency of research and development of new antibiotics
  • open sharing of knowledge between pharma industry and academi
  • addressing the barriers to clinical development of antibiotics
  • innovative trial designs to facilitate the registration of novel antibacterial agents
  • over fifteen international trials, involving both (registration) clinical trials with drugs under development and investigator-initiated research
  • a premier Europe-wide network of hospitals and laboratories prepared for and experienced in performing high-quality clinical studies
  • clock

    14:30

    Statistical and design approaches to allow more feasible antibiotic drug development

    Aaron Dane

    Aaron Dane, Director, Danestat consulting

    • A n outline of alternative statistical approaches and study
    designs are being considered and actively discussed
    with global regulatory agencies
    • H ow likely they are to be possible going forward
    • D iscussion of which approaches can already be applied
    and which require further work before being considered
    part of routine practice

    clock

    15:10

    Afternoon Tea

    clock

    15:30

    The development of antimicrobial peptides (AMP) as new antibacterial drugs

    Deborah O'Neil

    Deborah O'Neil, Chief Executive Officer, Novabiotics Ltd

    • Exploring AMP as a viable alternative to antibiotics
    • Utilising an AMP different mode of action
    • Latest developments in antimicrobial peptides

    clock

    16:10

    Short antimicrobial peptides - their potential to treat bacterial MDR infections

    Kai Hilpert

    Kai Hilpert, Prof Associate Reader in Infection and Immunology , St George's, University of London

    clock

    16:50

    Novel approaches to enabling antibacterial activity against Gram-negative pathogens

    Aileen  Rubio

    Aileen Rubio, Head of Biology, Spero Therapeutics

    • Combating Gram negative pathogens require
    innovative approaches in addition to the standard small
    molecules
    • We have identifi ed an outer membrane permeabilizer,
    SPR741, that helps otherwise impermeant antibiotics
    entry into the Enterobacteriaecaea.
    • Improvements in activity can be observed both in vitro
    and in vivo when SPR741 is combined with rifampin or
    other antibiotics

    clock

    17:30

    Chairman’s Closing Remarks and Close of Day One

    Richard Bax

    Richard Bax, Senior Partner, TranScrip Partners

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Lloyd Czaplewski

    Lloyd Czaplewski, Director, Chemical Biology Ventures

    clock

    9:10

    Antibiotic evaluation: Current challenges and the opportunities

    Nicole Mahoney, Global Regulatory Policy, MSD

    clock

    9:50

    How the pharmaceutical industry is helping address AMR?

    James Anderson

    James Anderson, Head of Government Affairs, GSK

    · The role of the pharmaceutical industry in combating AMR goes beyond investing in R&D for new antibiotics
    · Companies are partnering with healthcare systems globally to help ensure antibiotics are manufactured cleanly, available to patients where needed and used appropriately
    · We seek further progress on implementation of new economic models to deliver sustainable solutions for all.
     

    clock

    10:30

    Morning Coffee

    clock

    10:50

    The use of in vivo models for infectious disease research

    William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

    • Experimental Design of Animal Models
    • Bridging the gap – in vitro activity to in vivo effi cacy
    • Where to start / What model to use
    • What does the data tell us

    clock

    11:30

    Finding new small molecule antibiotics

    David Williams

    David Williams, Chief Executive Officer, Discuva

    clock

    12:10

    Networking Lunch

    clock

    13:10

    Fighting back against MBL mediated CREs: development of metallo-beta-lactamase inhibitors for use in combination with carbapenems

    Martin Everett

    Martin Everett, Chief Scientific Officer, Antabio

    • MBL-mediated CRE are already endemic in many countries
    and rapidly spreading world-wide
    • Antabio have identifi ed a potent and selective lead series
    with excellent drug-like properties
    • Lead compounds show broad spectrum potentiation of
    meropenem against clinical CRE isolates and demonstrate
    effi cacy in animal models of infection

    clock

    13:50

    Microbome-targeted products: Spare vs repair

    Jean de Gunzburg

    Jean de Gunzburg, CSO, Da Volterra

    • Antibiotic-induced dysbiosis and its consequences
    • FMT and microbiota-derived products aimed at
    C. diffi cile infections
    • Pharmacological interventions targeting the gut
    microbiome
    • Protecting the intestinal microbiome during antibiotic
    treatments

    clock

    14:30

    Afternoon Tea

    clock

    14:50

    Exploiting DNA topoisomerases as targets for antibacterial chemotherapy

    Anthony Maxwell

    Anthony Maxwell, Professor, John Innes Centre

    • AMR is a serious and growing problem
    • DNA topoisomerases (e.g. DNA gyrases) are successful
    and well-validated targets for antibiotics
    • Fluoroquinolones are highly-successful antibacterial
    agents, but resistance is a serious problem
    • Approaches to discover new gyrase inhibitors
    • Topoisomerases present new opportunities for antibiotic
    targeting

    clock

    15:30

    Anti-infective monoclonal antibodies against multi-drug resistant pathogens

    Eszter Nagy

    Eszter Nagy, President and CSO, Arsanis Biosciences GmbH

  • The benefit of mAbs with multiple modes of action and multi-specificity
  • Pre-emptive approach for high-risk patients is highly attractive
  • mAb therapy to increase antibiotic effectiveness with directly anti-bacterial and/or anti-virulence mechanisms
  • clock

    16:10

    Discovery of a novel class of antibiotics

    Richard Rutter

    Richard Rutter, Chief Scientific Officer, Auspherix Ltd

    • Identifi cation of a new class of broad-spectrum
    antibacterials
    • Antimicrobial profi les (Gram-positive & Gram-negative)
    • In-vitro characterisation and mechanistic insights

    clock

    16:50

    Novel oligonucleotide antimicrobials against Gram-negative infections

    Michael McArthur

    Michael McArthur, Chief Scientific Officer, Procarta Biosystems Ltd.

    · Rational design of oligonucleotide antimicrobials to target transcription factors
    · Identification of a new Gram-negative therapeutic target
    · Validation in microbiome and animal models

    clock

    17:30

    Chairman’s Closing Remarks and Close of Day Two

    Lloyd Czaplewski

    Lloyd Czaplewski, Director, Chemical Biology Ventures


    Director
    Danestat consulting
    Head of Biology
    Spero Therapeutics
    Professor
    John Innes Centre
    Branch Chief, Antibacterials Program
    BARDA
    Chief Executive Officer
    Discuva
    Chief Executive Officer
    Novabiotics Ltd
    Vice President of Development
    Synthetic Biologics, Inc.
    President and CSO
    Arsanis Biosciences GmbH
    Head of Government Affairs
    GSK
    CSO
    Da Volterra
    Prof Associate Reader in Infection and Immunology
    St George's, University of London
    Director
    Chemical Biology Ventures
    Chief Scientific Officer
    Antabio
    Chief Scientific Officer
    Procarta Biosystems Ltd.
    Global Regulatory Policy
    MSD
    Chief Scientific Officer
    Soligenix, Inc.
    Senior Partner
    TranScrip Partners
    Chief Scientific Officer
    Auspherix Ltd
    Project leader
    UMC Utrecht
    Director, Division of Anti-Infective
    FDA
    Director of Pre-Clinical Services
    University of North Texas Health Science Center
    CEO
    Eligo Bioscience

    Sponsors and Exhibitors

    Official Media Partner

    Official Publication

    Supporters

    Workshops

    The Use of Animal Models in Pre-Clinical Drug Development

    The Use of Animal Models in Pre-Clinical Drug Development

    Holiday Inn Kensington High Street
    22 March 2017
    London, United Kingdom

    Practical Challenges in Developing Novel Antimicrobials

    Practical Challenges in Developing Novel Antimicrobials

    Holiday Inn Kensington High Street
    22 March 2017
    London, United Kingdom

    An Interview with Deborah O’Neil, Chief Executive Officer, Novabiotics Ltd

    Download

    Soligenix, Inc. Literature

    Download

    An Interview with Joe Sliman, Chief Medical Officer, Synthetic Biologics, Inc.

    Download

    Attendee List Superbugs 2017

    Download

    An Interview with Martin Everett, Chief Scientific Officer, Antabio

    Download

    New Interview Out with Danestat Consulting in the Run-up to Superbugs 2017

    Download

    An Interview with the John Innes Centre Ahead of Superbugs & Superdrugs 2017

    Download

    Invitation Letter

    Download

    Sponsors and Exhibitors


    MSD

    Sponsors and Exhibitors
    http://www.msd.com/

    For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world's most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information, visit www.msd.com and connect with us on Twitter, LinkedIn and YouTube.


    Soligenix, Inc.

    Sponsors and Exhibitors
    http://www.soligenix.com

    Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is unmet medical need, including: 1) a therapeutics segment directed at cutaneous T-cell lymphoma and oral mucositis; and 2) a biodefense segment directed at ricin exposure, acute radiation syndrome and antibiotic resistant infectious disease.


    Synthetic Biologics

    Sponsors and Exhibitors
    http://www.syntheticbiologics.com

    Synthetic Biologics (NYSE MKT: SYN) is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients. Our lead programs poised for Phase III development include a beta-lactamase designed to protect the gut microbiome from residual intravenous antibiotics and a reformulation of lovastatin-lactone designed to reduce methane production in the gut.

    Media Partners


    Global Biodefense

    Official Media Partner
    http://www.globalbiodefense.com/

    Global Biodefense publishes the latest news on vaccine and therapeutics countermeasure development, biosurveillance and detection technologies, food safety and biosecurity, and CBRN incident preparedness and response. Visit our website to access daily news updates, organization profiles, conference listings, and the latest in funding opportunities for advancing biodefense technology.

    Media Partners


    Int. J. of Bioinformatics Research and Applications

    Official Publication
    http://www.inderscience.com/ijbra

    Bioinformatics is an interdisciplinary research field that combines biology, computer science, mathematics and statistics into a broad-based field that will have profound impacts on all fields of biology. The emphasis of IJBRA is on basic bioinformatics research methods, tool development, performance evaluation and their applications in biology. IJBRA addresses the most innovative developments, research issues and solutions in bioinformatics and computational biology and their applications.


    International Journal of Food Safety, Nutrition and Public Health

    Official Publication
    http://www.inderscience.com/jhome.php?jcode=ijfsnph

    IJFSNPH contributes to the improvement of public health through quality research and a better understanding of the science involved in food safety, nutrition and dietetics, food studies, food and restaurant management. To promote better health for all, this initiative aims to broaden the context of public health and health equity, integrate the study of these various disciplines, and foster knowledge transfer on key issues regarding the pivotal role of food safety, nutrition and health equity in influencing health outcomes.


    Int. J. of Biotechnology

    Official Publication
    http://www.inderscience.com/ijbt

    IJBT provides an international forum and refereed authoritative source of information in the field of Biotechnology and Biotechnics, with emphasis on management and economics, as well as the political and social issues. It aims to disseminate knowledge, provide a learned reference in the field, and establish channels of communication between academic and research experts, policy makers and executives in industry, commerce and investment institutions.


    International Journal of Risk Assessment and Management

    Official Publication
    http://www.inderscience.com/ijram

    IJRAM is an interdisciplinary and refereed journal that provides cross learning between: • Different business and economics, as well as scientific and technological, disciplines • Energy industries, environmental and ecological systems • Safety, public health and medical services • Software services, reliability and safety

    Media Partners


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    SelectScience

    Supporters
    http://www.selectscience.net/register?utm_source=Media-Partner&utm_medium=Website&utm_campaign=SMI

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover the latest drug discovery and development technologies, products and techniques with product reviews, videos, application notes and news articles. Become a member for free today.


    BioPharm Insight

    Supporters
    http://www.biopharminsight.com

    BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive online interface and exclusive Active IntelT relational content technology, BioPharm Insight provides an unrivaled capability to segment and analyze the industry with detailed and searchable profiles.


    KBI Biopharma

    Supporters
    http://www.kbibiopharma.com

    KBI also provides services from its industry-leading Particle Characterization Core Facility, including a full range of particle detection methods and data analysis utilizing MFI, Archimedes, NTA, Helix, Morphologi G3-ID, and Viscosizer instruments.


    Conference-Service.com

    Supporters
    http://www.conference-service.com/

    COMS is a web application for managing delegate registration, payment, paper submission and paper review. Written in Perl and C, with a MySQL database at the back end, it is a comprehensive and powerful, yet easy to use solution for online conference management.


    Pharmiweb

    Supporters
    http://www.pharmiweb.com

    Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.


    PharmaVOICE

    Supporters
    http://www.pharmavoice.com

    PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.


    Farmavita

    Supporters
    https://farmavitar.com

    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!


    Bentham Science

    Supporters
    http://www.benthamscience.com/

    Bentham Science Publishers is a major STM journal publisher of 130 plus print and online journal. Out of these, 40 journals have already registered good IMPACT FACTORS as per Journal Citation Reports® 2017. These titles have extensive readership mostly in Europe and North America. For a detailed profile please visit our website at http://www.benthamscience.com. Besides, Bentham Science publishes eBooks in all areas of Science, Technology and Medicine. Our eBooks provide professionals, academicians, corporate researchers, graduates and undergraduates worldwide with the most current information in their subject areas of interest. Our eBooks are also available in the ePub and Kindle formats besides the PDF edition here http://ebooks.benthamscience.com/. Bentham is offering attendees of this conference discounts on its publication. For more information click here


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.


    Labiotech.eu

    Supporters
    https://goo.gl/DRE2Gp

    Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


    CanBiotech

    Supporters
    http://www.canbiotech.com

    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


    Drug Target Review

    Supporters
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    PMR

    Supporters
    http://www.pmrcorporate.com

    PMR (www.pmrcorporate.com) is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern European countries as well as other emerging markets. PMR's key areas of operation include business publications (through PMR Publications), consultancy (through PMR Consulting) and market research (through PMR Research ). Being present on the market since 1995, offering high international standards in projects and publications, as well as providing one of the most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.


    Copybook - Pharmaceutical

    Supporters
    http://www.copybook.com/pharmaceutical

    Copybook is a global business network with many pharmaceutical events, exhibitions and seminars. We encourage business-to-business transactions and work tirelessly to gain our customers new business contracts worldwide. You can add events, companies and associations for free. When you are a member, you can add your company to the events listed in order to encourage other visitors to arrange meetings and appointments at those events to facilitate new business contracts. Want to see how we can increase your business network and transactions? SIGN UP FOR FREE today! Copybook – Your Global Business Network


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    GBI

    Supporters
    http://www.gbihealth.com/

    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    International Pharmaceutical Industry

    Supporters
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    Labhoo

    Supporters
    http://www.labhoo.com



    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    British Pharmacological Society

    Supporters
    http://www.bps.ac.uk

    The British Pharmacological Society (BPS) is the primary UK learned society concerned with research into drugs and the way they work. Our members work in academia, industry, regulatory agencies and the health services, and many are medically qualified. The Society covers the whole spectrum of pharmacology, including laboratory, clinical, and toxicological aspects. Clinical pharmacology is the medical speciality dedicated to promoting safe and effective use of medicines for patient benefit. Clinical pharmacologists work as consultants in the NHS and many hold prominent positions in UK Universities.


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.